|Bid||0.00 x 800|
|Ask||53.65 x 900|
|Day's Range||53.01 - 54.18|
|52 Week Range||39.11 - 73.89|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||671.88|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.00|
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 92.06% and 14.49%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Q3 2019 performance above guidance Full year 2019 financial forecast reaffirmed GAITHERSBURG, Md., Nov. 06, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial.
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
GAITHERSBURG, Md., Oct. 21, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New.
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.
Yahoo Finance Premium members have access to the full 30-stock Argus Focus List. Activision creates video games. The company’s top game franchises include “Call of Duty,” “Diablo,” and “World of Warcraft.” Activision acquired King Digital Entertainment, the producer of the “Candy Crush” mobile puzzle game, in February 2016.
Emergent BioSolutions Inc. (EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) during its September meeting. The PRIME scheme is designed to enhance support for the development of medicines that target an unmet medical need and that may offer a major therapeutic advantage over existing treatments, or benefit patients without preventative or treatment options.
GAITHERSBURG, Md., Oct. 09, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the.
Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.
Emergent BioSolutions Inc. (EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), U.S. Department of Health and Human Services, valued at approximately $6.3 million over two years, for the continued development of AP007, the company’s sustained-release nalmefene formulation for the treatment of addiction in opioid use disorder (OUD). AP007 is an extended-release formulation of nalmefene, an opioid receptor antagonist, intended to continually release an effective dose of nalmefene for up to three months and to be administered through intramuscular injection.
GAITHERSBURG, Md., Sept. 26, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor.
Emergent BioSolutions Inc. (EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve agent-induced seizures. Emergent’s device is being designed for intramuscular buddy-administration for use in military environments and for civilian emergencies. Doug White, SVP and devices business unit head at Emergent BioSolutions, stated, “Emergent is pleased with this follow-on contract, which expands our opportunities to serve the needs of the Department of Defense (DoD) for modern and reliable auto-injectors to protect our military personnel against nerve agents.
Emergent Biosolutions Inc (NYSE: EBS ) Tuesday announced a follow-on U.S. government contract for its smallpox vaccine, ACAM2000. There had been widespread investor concern around the delay in this contract, ...
In support of the U.S. government’s policy to maintain a stockpile to be able to protect every American from smallpox, Emergent BioSolutions Inc. (EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $2 billion over 10 years for the continued supply of ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (SNS). The actual number of ACAM2000 doses to be procured is dependent on certain timing and tiered-pricing terms that are subject to the discretion of ASPR.
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.